Starting Oct. 1, the insurer will require clinicians and labs who order genetic and molecular tests for their patients to first get approval.
The test is now covered by Premera Blue Cross, a regional health plan with more than 2 million members located primarily in Washington, Oregon, and Alaska.
Among the tests that French national health insurance system will reimburse are IGRA tests, including ones from Qiagen and Oxford Immunotec, for screening TB.
The long-term pricing contract covers hereditary cancer testing, GeneSight, and a number of other diagnostics, but doesn't extend to coverage.
The company said the number of lives now covered for EndoPredict has gone up to 109 million.
Winship's director of the cancer tissue and pathology shared resource said that some labs aren't leveraging molecular technologies due to reimbursement issues.
The AACC called for increased collaboration between physicians and laboratory medicine professionals, as Medicare changes how it reimburses for clinical lab tests.
With PAMA scheduled to be implemented in January, many believe M&A in the clinical lab space will heat up, with Quest and LabCorp the main beneficiaries.
The company said it now has payor coverage for more than 130 million individuals.
The company obtained out-of-state provider status from California's Medicaid program for its OVA1 test, giving it access to more than 12 million patients.